DBV Technologies SA Q3 FY2026 earnings call

• BLA Submission: Successfully filed the Biologics License Application (BLA) for Viaskin Peanut Patch in children aged 4-7 years with the FDA.
• Manufacturing Remediation: Addressed an FDA Warning Letter received by contract manufacturer Fareva Ambroise in April 2026 regarding quality management systems from a veterinary product inspection. Fareva is executing a remediation plan with third-party consultants; DBV maintains close oversight to ensure relevance to peanut patch manufacturing.
• Toddler Program Strategy: Discussed a sequential review approach with the FDA for the upcoming BLA in toddlers (aged 1-3). The agency prefers reviewing the 4-7 application first to avoid bottlenecks and leverage learnings, with toddler data submission expected in 2027.
• Commercial Preparation: Aggressively building commercial infrastructure, including hiring sales and marketing teams, engaging with payers, and establishing market access strategies ahead of potential launch.
• Cash Position: Maintained $165.7 million in liquidity, including $50 million raised via an ATM program, sufficient to fund operations into Q3 2027.

As a clinical-stage biotechnology company developing a single product candidate (Viaskin Peanut Patch), DBV Technologies does not report revenue or segmented financial performance. The company incurred operating expenses of $164.6 million for the third quarter of 2026, an increase from $107 million in the prior year period. Cash and cash equivalents stood at $165.7 million at the end of the quarter.

• Cash Runway: Management updated its liquidity forecast, stating that existing cash reserves are sufficient to fund operations through the third quarter of 2027.
• Regulatory Timeline: Confirmed readiness for Pre-Approval Inspection (PAI) by February 1, 2027. No specific approval date guidance was provided, but planning assumes a Priority Review timeline.
• Toddler BLA: Expects to submit the BLA for the 1-3 age group in 2027, following final alignment with the FDA on submission timing and content.
• Financial Guidance: Explicitly stated that no sales guidance or revenue projections will be provided until closer to the potential launch date.

• Manufacturing Quality Issues: The FDA Warning Letter at Fareva Ambroise carries site-wide implications for quality management systems, potentially impacting the PAI and approval timeline if remediation is insufficient.
• Regulatory Bottlenecks: Risk that submitting two BLAs in quick succession could delay the review process; however, management has aligned with the FDA on a sequential strategy to mitigate this.
• Supply Chain Concentration: Reliance on a single manufacturing site (Fareva) for initial launch; establishing redundant supply capacity takes approximately three years, leaving limited near-term backup options.
• Clinical Data Uncertainty: While the 'Comfort Toddlers' safety study is expected to show consistent results, it remains a supplemental study, and final regulatory acceptance of the data package is pending.

Q: Analyst asked if Fareva shares monthly remediation updates with DBV and when the FDA re-inspection might be scheduled.

A: CEO Daniel Tassé confirmed that while Fareva shares adequate progress reports, they do not disclose all details due to serving other clients. He noted the FDA re-inspection has not yet been scheduled and would be premature to announce at this stage.

Q: Analyst inquired about the rationale for the sequential BLA submission strategy (4-7 first, then 1-3) and whether the toddler BLA would wait for the completion of the first review.

A: CMO Pharis Mohideen explained that the FDA requested this sequence to prevent review bottlenecks and allow the agency to build on learnings from the first application. This approach supports an efficient priority review for the 4-7 cohort without delaying the subsequent toddler submission.

Q: Analyst questioned the focus of the FDA warning letter and whether DBV plans to secure a second manufacturer for redundancy.

A: COO Kevin Malobisky clarified the warning letter stemmed from a veterinary aseptic manufacturing process, distinct from peanut patch production, though site-wide quality systems were cited. CEO Tassé added that while a second facility is needed for long-term scale, it takes ~3 years to build, so the immediate plan relies on resolving Fareva’s issues rather than seeking a backup supplier.

Q: Analyst asked if DBV expects Priority Review for the 4-7 BLA and if they can monetize a Priority Review Voucher (PRV).

A: Tassé affirmed that Priority Review is expected given Breakthrough Therapy designation, and all planning assumes this tight timeline. Regarding PRVs, he explained that strict rules likely disqualify Viaskin because the technology applies to broader populations beyond just pediatrics, making monetization unlikely.

Q: Analyst asked about the nature of the 'Comfort Toddlers' safety study results and early payer discussions.

A: CMO Mohideen described the toddler safety press release as a "check-the-box" event, expecting no new safety signals given the established profile of the product. CEO Tassé noted that payer engagement is ongoing, with account managers already discussing pricing and prioritization processes with major US insurers to prepare for launch.